---
figid: PMC5528622__MOL2-8-1140-g003
figlink: /pmc/articles/PMC5528622/figure/mol22014861140-fig-0003/
number: Figure 3
caption: Mechanisms of resistance to targeted therapies in melanoma. The remarkable
  clinical efficacy of BRAF inhibitors in mutant BRAF melanoma is limited by acquired
  and intrinsic drug resistance, with several mechanisms having been described. Upstream
  the RAS/RAF/MEK/ERK pathway, activation or upregulation of RTKs such as IGF‐1R,
  PDGFRα and EGFR signalling through SFKs (SRC family kinases). Downstream the RTKs,
  on the RAS/RAF/MEK/ERK axis, mutations in RAS, amplification of CRAF and BRAF, expression
  of truncated BRAF, mutations in MEK or increased expression of MAP3K8/COT or MLK1‐4.
  Downstream the RTKs, on alternative signalling pathways, deletions in PTEN and mutations
  in PI3K and AKT. * indicates mutations or activation/upregulation.
pmcid: PMC5528622
papertitle: 'No longer an untreatable disease: How targeted and immunotherapies have
  changed the management of melanoma patients.'
reftext: Maria Romina Girotti, et al. Mol Oncol. 2014 Sep;8(6):1140-1158.
pmc_ranked_result_index: '3999'
pathway_score: 0.9505764
filename: MOL2-8-1140-g003.jpg
figtitle: Resistance to targeted therapies in melanoma
year: '2014'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5528622__MOL2-8-1140-g003.html
  '@type': Dataset
  description: Mechanisms of resistance to targeted therapies in melanoma. The remarkable
    clinical efficacy of BRAF inhibitors in mutant BRAF melanoma is limited by acquired
    and intrinsic drug resistance, with several mechanisms having been described.
    Upstream the RAS/RAF/MEK/ERK pathway, activation or upregulation of RTKs such
    as IGF‐1R, PDGFRα and EGFR signalling through SFKs (SRC family kinases). Downstream
    the RTKs, on the RAS/RAF/MEK/ERK axis, mutations in RAS, amplification of CRAF
    and BRAF, expression of truncated BRAF, mutations in MEK or increased expression
    of MAP3K8/COT or MLK1‐4. Downstream the RTKs, on alternative signalling pathways,
    deletions in PTEN and mutations in PI3K and AKT. * indicates mutations or activation/upregulation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K2
  - IGF1R
  - MAP2K1
  - PTEN
  - AKT1
  - NRAS
  - PDGFRB
  - MAPK3
  - MAPK1
  - BRAF
  - CROT
  - AKT3
  - RAF1
  - EGFR
  - AKT2
  - Cancer
  - Lung cancer
genes:
- word: '*MEK'
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: '*IGF-1R'
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: '*MEK'
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: '*PTEN'
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: '*AKT'
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: '*NRAS'
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: '*PDGFRB'
  symbol: PDGFRB
  source: hgnc_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: '*COT'
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: '*AKT'
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: '"""EGFR"'
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: '*AKT'
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
